Rainer Westermann

Rainer Westermann
Rainer Westermann is the Chairman of the Life Sciences Acceleration Alliance e.V., Munich, a European non-profit coalition dedicated to educating and conveying knowledge about venture capital financing in the life sciences sector in Europe. LSAA aims to improve the entrepreneurial environment for young and innovative companies in life sciences in Europe and to create a reliable legal framework for corresponding investments and venture capitalists. Rainer is a Board Member and former President of the Crisis Protection Network, Zurich, an international network of reputation management advisors. He serves on the Advisory Board of the TUM Institute for LifeLong Learning, Munich, as …
Rainer Westermann is the Chairman of the Life Sciences Acceleration Alliance e.V., Munich, a European non-profit coalition dedicated to educating and conveying knowledge about venture capital financing in the life sciences sector in Europe. LSAA aims to improve the entrepreneurial environment for young and innovative companies in life sciences in Europe and to create a reliable legal framework for corresponding investments and venture capitalists.

Rainer is a Board Member and former President of the Crisis Protection Network, Zurich, an international network of reputation management advisors. He serves on the Advisory Board of the TUM Institute for LifeLong Learning, Munich, as well as teaching as a lecturer at the TUM School of Management.

As Principal of Westermann Advisors, Rainer advises and supports clients in situations with a high reputation risk, focusing on strategic communications, reputation management and crisis as well as litigation response.

During his career, he was advisor to senior management for a broad range of blue-chip companies in Germany, Canada and the USA. He managed professional services firms and, as a corporate officer, was responsible for building, improving and protecting corporate reputation.

As Corporate Vice President of Infineon Technologies, a German DAX 30 corporation, he was responsibile for the corporate brand, marketing communications, government relations as well as external and internal communications. He was named CEO Germany for FleishmanHillard and later Burson-Marsteller, two of the leading international communications consultancies.

Rainer spent six years in North America, where he was a Member of the Management Board of LHS Group, an Atlanta based NASDAQ and Neuer Markt listed software company. He represented the company as corporate spokesperson towards the global investment community and the media. In Toronto, he built a successful corporate communications and investor relations practice for FleishmanHillard Canada. He joined the consultancy originally in Frankfurt, when he founded Fleishman-Hillard Germany, a joint venture formed from his own marketing communications agency. During his career, Rainer supported a number of clients in the health care sector and worked in-house for the medical products division of DuPont.
See more

Articles: Rainer Westermann

EU Pharma Legislation: An Opportunity to Rethink

Europe / Rainer Westermann of venture capitalist coalition Life Sciences Acceleration Alliance reviews the potential impact of the EU’s general pharmaceutical legislation on the investment climate for the EU life sciences sector. Building on his insights from last year, Westermann urges stakeholders to seize the opportunity caused by a delay in the upcoming EU parliamentary elections to…

EU Pharma Reform: A Medicine with Serious Side Effects 

Europe / Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, critiques the draft EU Pharma Regulation from a VC perspective, arguing that the continent’s status as a medical innovation hub is at risk if the EU Commission continues to fail to…

EU Drug Shortage is a Result of Over-Regulation & Focus on Cost Cutting 

Europe / Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, launches a critique of current pharmaceutical policies across the EU, arguing that constant cost-containment measures, over-regulation, and bureaucracy are leading to drug shortages and acting as a bottleneck for the continent’s…

See more